Find something to look at
Browse by category, see the connections as a graph, check out what's being tested in patients right now, or see the latest FDA approvals.
Disease ↔ gene ↔ drug
See the connections as a graph
Three things connect everything: diseases, the genes involved in them, and the drugs that act on those genes. Pick a disease and we'll draw the picture: which genes drive it, and which existing drugs hit those genes.
By category
Pick a body system or disease family. Click any condition to see drugs that might also help it.
Cancer
Solid tumors, blood cancers, and rare oncology.
Heart & vessels
Cardiovascular disease, blood pressure, clotting.
Brain & nerves
Neurodegeneration, dementia, movement, headache.
Mental health
Mood, anxiety, attention, addiction.
Immune & autoimmune
When the body's defenses go wrong.
Metabolism & weight
Diabetes, obesity, thyroid, liver, hormones.
Drugs being tested in patients right now
The most-recent Phase II / Phase III studies that are actively recruiting people. Pulled live from ClinicalTrials.gov.
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin an…PHASE3For: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8Bleomycin SulfateBrentuximab VedotinCyclophosphamideDacarbazineNCT05675410● recruiting
- ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerPHASE3For: Breast NeoplasmsPumitamigNab-paclitaxel/Paclitax…GemcitabineCarboplatinNCT07173751● recruiting
- A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderPHASE3For: Major Depressive Disorder (MDD), Depression in Adults +4 moreCYB003NCT06793397● recruiting
- Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.PHASE2, PHASE3For: Lymphatic MalformationsAlpelisibPlaceboNCT05948943● recruiting
- Phase IIIb Study of Ribociclib + ET in Early Breast CancerPHASE3For: Early Breast CancerRibociclibLetrozoleAnsastrozoleGoserelinNCT05827081● recruiting
- A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo…PHASE3For: Autoimmune Haemolytic AnaemiarilzabrutinibplaceboNCT07086976● recruiting
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in…PHASE3For: Non Small Cell Lung CancerSacituzumab tirumotecanPembrolizumabCisplatinPemetrexedNCT06312137● recruiting
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cycloph…PHASE3For: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 +2 moreCyclophosphamideDoxorubicinDurvalumabPaclitaxelNCT06058377● recruiting
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in…PHASE3For: NMDAR Autoimmune Encephalitis, LGI1 Autoimmune EncephalitisSatralizumabNCT05503264● recruiting
- Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Childre…PHASE3For: VasculitisAvacopanNCT06321601● recruiting
- The Effect of Erector Spinae Plane Block (ESPB) on Pediatric Pain Management Following Posterior Spinal Fusio…PHASE3For: Adolescent Idiopathic Scoliosis (AIS), Neuromuscular Scoliosis +1 moreRopivacaine HydroclorideNCT07561827● recruiting
- HEALEY ALS Platform Trial - Master ProtocolPHASE2, PHASE3For: Amyotrophic Lateral SclerosisZilucoplanVerdiperstatCNM-Au8PridopidineNCT04297683● recruiting
Notable recent FDA approvals
A hand-picked tour of new medicines that reached patients in the last couple of years. Click into any one to see what else it might also help.
Leqembi
2023lecanemabApproved for early Alzheimer's disease.First antibody to slow Alzheimer's progression, by clearing amyloid plaques from the brain.
See its profile →Kisunla
2024donanemabApproved for early Alzheimer's disease.Second-generation amyloid antibody — limited-duration treatment, stops once plaques clear.
See its profile →Rezdiffra
2024resmetiromApproved for advanced fatty liver disease (MASH).First drug ever approved for non-alcoholic steatohepatitis — a condition affecting tens of millions.
See its profile →Zepbound
2023tirzepatideApproved for obesity.GLP-1/GIP dual receptor agonist; the most effective weight-loss medication in trials to date.
See its profile →Winrevair
2024sotaterceptApproved for pulmonary arterial hypertension.First-in-class activin signaling inhibitor for a rare, progressive lung condition.
See its profile →Amtagvi
2024lifileucelApproved for advanced melanoma.First cellular therapy for a solid tumor — uses the patient's own T cells against the cancer.
See its profile →Truqap
2023capivasertibApproved for HR+/HER2- breast cancer.Targets the AKT pathway in tumors that have become resistant to hormone therapy.
See its profile →Wegovy
2024semaglutideApproved for cardiovascular risk reduction.Already approved for obesity; new indication shows it cuts heart-attack risk in overweight adults.
See its profile →